<DOC>
	<DOC>NCT01259908</DOC>
	<brief_summary>Patients with aorto-iliac occlusive disease (TASC, type D) operated with a totally laparoscopic aortobifemoral bypass operation and open aortobifemoral bypass operation will be followed up and the results will be compared between the two procedures on the basis of the primary endpoint, a composite endpoint defined as a combined incidence of systemic morbidity, graft thrombosis and all-cause mortality.</brief_summary>
	<brief_title>Laparoscopic Surgical Treatment of Aorto-iliac Occlusive Disease</brief_title>
	<detailed_description>Patients with aorto-iliac occlusive disease (TASC, type D) operated with a totally laparoscopic aortobifemoral bypass operation and open aortobifemoral bypass operation will be followed up and the results will be compared between the two procedures on the basis of the primary endpoint, a composite endpoint defined as a combined incidence of systemic morbidity, graft thrombosis and all-cause mortality. Secondary endpoints like length of hospital stay, operation time, bleeding time shall also be considered. Besides short form- 36 (SF-36) shall be used for the evaluation of patients health related quality of life, preoperatively,1,3,and 6 months and 1 year post-operatively. Early, midterm and long time results shall be followed.</detailed_description>
	<mesh_term>Leriche Syndrome</mesh_term>
	<criteria>All patients with a TASC D lesion in the aortoiliac segment not amenable to or previously unsuccessfully treated by endovascular approach. Unsuitable for surgery due to general health status</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>laparoscopic aortic surgery</keyword>
	<keyword>aorto-iliac occlusive disease</keyword>
</DOC>